Ignyta (United States)

Recent papers from Ignyta (United States)

1. Expanding the landscape of oncogenic drivers and treatment options in acral and mucosal melanomas by targeted genomic profilingInternational Journal of Cancer · 2024
2. Entrectinib in children and young adults with solid or primary CNS tumors harboring NTRK, ROS1, or ALK aberrations (STARTRK-NG)Neuro-Oncology · 2022
3. Characterization of the pharmacokinetics of entrectinib and its active M5 metabolite in healthy volunteers and patients with solid tumorsInvestigational New Drugs · 2021
4. Colorectal Adenocarcinomas Harboring ALK Fusion GenesThe American Journal of Surgical Pathology · 2020
5. Opportunities and challenges in developing tissue-agnostic anti-cancer drugsJournal of Cancer Metastasis and Treatment · 2020
6. Mapping actionable pathways and mutations in brain tumours using targeted RNA next generation sequencingActa Neuropathologica Communications · 2019
7. Colonic Adenocarcinomas Harboring NTRK Fusion GenesThe American Journal of Surgical Pathology · 2019
8. Immuno-oncological Efficacy of RXDX-106, a Novel TAM (TYRO3, AXL, MER) Family Small-Molecule Kinase InhibitorCancer Research · 2019
9. Genomic Analysis of Posterior Fossa Meningioma Demonstrates Frequent AKT1 E17K Mutations in Foramen Magnum MeningiomasJournal of Neurological Surgery Part B Skull Base · 2019
10. RET fusions in a small subset of advanced colorectal cancers at risk of being neglectedAnnals of Oncology · 2018
11. Novel TLE4‐NTRK2 fusion in a ganglioglioma identified by array‐CGH and confirmed by NGS: Potential for a gene targeted therapyNeuropathology · 2018
12. Intratumoral heterogeneity and TERT promoter mutations in progressive/higher-grade meningiomasOncotarget · 2017
13. Molecular Profiling of Mammary Analog Secretory Carcinoma Revealed a Subset of Tumors Harboring a Novel ETV6-RET TranslocationThe American Journal of Surgical Pathology · 2017
14. Identification and characterization of a novel SCYL3-NTRK1 rearrangement in a colorectal cancer patientOncotarget · 2017
15. ALK, ROS1, and NTRK Rearrangements in Metastatic Colorectal CancerJNCI Journal of the National Cancer Institute · 2017
16. Detecting Gene Rearrangements in Patient Populations Through a 2-Step Diagnostic Test Comprised of Rapid IHC Enrichment Followed by Sensitive Next-Generation SequencingApplied immunohistochemistry & molecular morphology · 2016
17. What hides behind the MASC: clinical response and acquired resistance to entrectinib after ETV6-NTRK3 identification in a mammary analogue secretory carcinoma (MASC)Annals of Oncology · 2016
18. Combating autophagy is a strategy to increase cytotoxic effects of novel ALK inhibitor entrectinib in neuroblastoma cellsOncotarget · 2015
19. Novel CAD-ALK gene rearrangement is drugable by entrectinib in colorectal cancerBritish Journal of Cancer · 2015
20. Sensitivity to Entrectinib Associated With a Novel LMNA-NTRK1 Gene Fusion in Metastatic Colorectal CancerJNCI Journal of the National Cancer Institute · 2015